AGENDA
9:45 AM EST
Webinar Opening Remarks
10:00 AM - 11:30 AM EST
Adapting a Quality Anti-Corruption and Anti-Fraud Risk Management Program and Dashboard for Effective Risk Based Monitoring
Part 1 – Best Practices for Building a Global Monitoring Plan and Strategy
Part 2 – Best Practices for Third Party Risk Management
Part 3 – Best Practices for HCP Engagement Strategies
Joe Mack, Senior Assistant General Counsel, Compliance & Investigations, Bayer
George Mina, Senior Director - International Compliance Monitoring, Pfizer
Roberta Rima, Director, Internal Audit, Gilead
Moderator - James Gargas, Partner, PricewaterhouseCoopers LLP
11:30 AM - 11:45 AM EST
Break
11:45 AM- 1:15 PM EST
How Analytics Helps Compliance Teams Manage Risks - Best Practices for Integrating Data Analytics into Your Risk Management Program
Jacob T. Elberg, Associate Professor, Seton Hall University School of Law, Cynthia Cetani, Chief Integrity & Compliance Officer, Indivior
Moderator – Parth Chanda, CEO, Lextegrity
1:15 PM - 1:45 PM EST
Break
1:45 PM - 2:45 PM EST
Best Practices for Risk Assessment and Mitigation Strategies to the COVID-19 Era
Sujata Dayal, VP & Chief Compliance Officer, G & A, Medline Industries, Inc.
Moderator – Seth Lundy, Partner, King and Spalding
2:45 PM - 3:15 PM EST
Break
3:15 PM - 4:45 PM EST
Best practices for right sizing your risk assessment based on company size
Elise Roth, General Counsel and Chief Compliance Officer, Medicem Inc.
Alondra Diaz, Compliance Vice President & Assistant General Counsel, Pfizer
Moderator - Gary Giampetruzzi, Partner, Paul Hastings
RISK MANAGEMENT
Adapting a Quality Risk Management Program and Creating a Dashboard for Effective Risk Based Monitoring
Global life sciences organizations grapple every day with enormous risks (including bribery, corruption and fraud related to HCPs, HCOs and their supply chains more broadly), as evidenced by continued investigations and resolutions between companies and government regulators globally. Risk management and mitigation programs are a hallmark of effective compliance programs at life sciences companies. Just as the life sciences industry has been significantly impacted by COVID-19 on many fronts, so has the approach to risk assessment and mitigation. This workshop will discuss evolving strategies to identify and assess known and novel risk factors as we rise to meet the challenges of today’s world. The workshop will examine best-in-class in compliance risk monitoring and management techniques for both small and large companies fit for the virtual environment using accessible, impactful technologies (such as integrating data analytics into your risk management program) to heighten insights surrounding commercial and medical interactions with customers, patients, and other third parties. At a time when field-based monitoring activities are increasingly constrained, gaining access to these insights through efficient use of advanced technology has never been more important for compliance executives.
Top Reasons to Attend:
- Engage with industry thought leaders on risk assessment strategies in a rapidly changing environment
- Learn best practices in risk assessment techniques
- Hear how peer companies are re-evaluating existing business practices in the risk assessment framework
- Learn how the all-virtual working environment is impacting data collection and analysis processes
- Get pointers on executive and employee engagement during the risk assessment process in the current environment
- Learn how COVID-19 is impacting risk registers and risk scoring
- Hear how companies are evolving their risk monitoring techniques
- Learn how to adapt technology to improve the risk detection and evaluation process
- Discuss best practices for integrating risk assessment into a comprehensive risk assessment and mitigation program
- Learn how best to conduct third party audits in a pandemic
- Learn how to create a comprehensive third-party risk management program
- Best practices for infusing a third-party risk management program with data analytics that add value to multiple organizational stakeholders
- Understand international legal considerations for third-party risk management
- Hear real life challenges and practical and legal considerations on conducting virtual speaker programs, how to ensure a legitimate program within your compliance safeguards
- Learn practical strategies to investigate allegations of HCP engagement improprieties during a pandemic
Personnel in the Following Environments Should Attend:
- Compliance and Ethics
- Compliance and Monitoring
- Legal/Counsel
- Internal Audit
- Risk Management
- Anti-Bribery and Anti-Corruption
- Third Party
- Data Analytics
*This workshop will also benefit consultants, tech vendors, and companies providing services to the above audience
PRESENTING SPONSORS
Lextegrity provides innovative enterprise analytics and automation software to prevent and detect risks related to fraud, corruption, sanctions and conflicts of interest. Our software manages risk across the spend lifecycle – from spend approval and due diligence to spend monitoring using data analytics. Lextegrity’s first-of-its-kind software is created by in-house counsel for in-house counsel and drives more efficient and more effective compliance programs.
Website: https://www.lextegrity.com/
Our purpose is clear in today’s world of transformative change — to help our clients and people navigate new paths to growth.
Founded in 1951, Paul Hastings has grown strategically to anticipate and respond to our clients’ needs in markets worldwide. Our innovative approach and unmatched client service have helped guide our journey to becoming one of the world’s leading global law firms in such a short time. With a strong presence throughout Asia, Europe, Latin America, and the U.S., we bring an international, interdisciplinary approach to support our life sciences and healthcare clients’ multifaceted needs. Our leading practice provides strategic legal counsel on critical intellectual property and helps clients navigate compliance, investigations, and enforcement issues, including FDA oversight throughout the product lifecycle. We also help clients structure transactions and financing arrangements, develop first-of-their-kind innovative strategic partnerships and licensing agreements, and advise on unique data governance issues, IoT development, and roll-out, as well as proactive privacy/cybersecurity assessments. Our leading lawyers also work closely with our Life Sciences Consulting Group members to design, build, implement, and operate effective compliance risk management programs.
Website: https://www.paulhastings.com/